Related Experiment Videos

Bisphosphonates: mechanisms of action

G A Rodan¹, H A Fleisch

¹Department of Bone Biology & Osteoporosis, Merck Research Laboratories, West Point, Pennsylvania 19486, USA. rodan@merck.com

The Journal of Clinical Investigation

|June 15, 1996

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Alendronate: preclinical studies.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008

Prostaglandin E2 (PGE2) increases the number of rat bone marrow osteogenic stromal cells (BMSC) via binding the EP4 receptor, activating sphingosine kinase and inhibiting caspase activity.

Prostaglandins, leukotrienes, and essential fatty acids·2006

Preservation of thoracic spine microarchitecture by alendronate: comparison of histology and microCT.

Bone·2005

Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins.

Cell death and differentiation·2004

M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.

Cell death and differentiation·2003

Preclinical safety profile of alendronate.

International journal of clinical practice. Supplement·2003

See all related articles